WO2024026029A3 - Lipid nanoparticles for immunotherapy - Google Patents

Lipid nanoparticles for immunotherapy Download PDF

Info

Publication number
WO2024026029A3
WO2024026029A3 PCT/US2023/028864 US2023028864W WO2024026029A3 WO 2024026029 A3 WO2024026029 A3 WO 2024026029A3 US 2023028864 W US2023028864 W US 2023028864W WO 2024026029 A3 WO2024026029 A3 WO 2024026029A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunotherapy
lipid nanoparticles
lnps
compositions
nucleic acid
Prior art date
Application number
PCT/US2023/028864
Other languages
French (fr)
Other versions
WO2024026029A2 (en
Inventor
Xin KAI
Qiaobing Xu
Original Assignee
Trustees Of Tufts College
Hopewell Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trustees Of Tufts College, Hopewell Therapeutics, Inc. filed Critical Trustees Of Tufts College
Publication of WO2024026029A2 publication Critical patent/WO2024026029A2/en
Publication of WO2024026029A3 publication Critical patent/WO2024026029A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed are compositions and methods related to lipid nanoparticles (LNPs) comprising ionizable lipids. The LNPs can comprise nucleic acid sequences encoding therapeutic peptides for immunotherapy, for example, bispecific antibodies or antigen binding fragments thereof.
PCT/US2023/028864 2022-07-27 2023-07-27 Lipid nanoparticles for immunotherapy WO2024026029A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263392800P 2022-07-27 2022-07-27
US63/392,800 2022-07-27
US202363510616P 2023-06-27 2023-06-27
US63/510,616 2023-06-27

Publications (2)

Publication Number Publication Date
WO2024026029A2 WO2024026029A2 (en) 2024-02-01
WO2024026029A3 true WO2024026029A3 (en) 2024-04-04

Family

ID=89707189

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/028864 WO2024026029A2 (en) 2022-07-27 2023-07-27 Lipid nanoparticles for immunotherapy

Country Status (1)

Country Link
WO (1) WO2024026029A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150283178A1 (en) * 2014-04-07 2015-10-08 Carl H. June Treatment of cancer using anti-cd19 chimeric antigen receptor
WO2021077067A1 (en) * 2019-10-18 2021-04-22 The Trustees Of The University Of Pennsylvania Lipid nanoparticles and formulations thereof for car mrna delivery
WO2021138600A1 (en) * 2019-12-31 2021-07-08 Fred Hutchinson Cancer Research Center Nanoparticle systems to stimulate and maintain immune system responsiveness at treatment sites

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150283178A1 (en) * 2014-04-07 2015-10-08 Carl H. June Treatment of cancer using anti-cd19 chimeric antigen receptor
WO2021077067A1 (en) * 2019-10-18 2021-04-22 The Trustees Of The University Of Pennsylvania Lipid nanoparticles and formulations thereof for car mrna delivery
WO2021138600A1 (en) * 2019-12-31 2021-07-08 Fred Hutchinson Cancer Research Center Nanoparticle systems to stimulate and maintain immune system responsiveness at treatment sites

Also Published As

Publication number Publication date
WO2024026029A2 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
AU2018298422A1 (en) Novel nucleic acid molecules
WO2017193032A3 (en) Bispecific binding proteins and uses thereof
WO2021018859A3 (en) Antibodies binding to gprc5d
EP4039710A3 (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
SG10201806839PA (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors
WO2021064137A3 (en) Multi-specific binding proteins for cancer treatment
WO2007028574A3 (en) Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules
WO2019197567A3 (en) Antigenic peptides for prevention and treatment of cancer
EP3854801A3 (en) Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
CR20200516A (en) Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
PH12020551907A1 (en) Antagonizing cd73 antibody
MX348154B (en) IL-1ß BINDING ANTIBODIES AND FRAGMENTS THEREOF.
EP2562183A8 (en) Novel immunogenic epitopes for immunotherapy
BR112022001923A2 (en) Antigen binding protein, isolated nucleic acid, recombinant host cell, pharmaceutical composition, antigen binding protein production method
WO2021094562A3 (en) Antigenic peptides for prevention and treatment of b-cell malignancy
EP2275435A3 (en) Streptococcus agalactiae antigens I + II
CR20210054A (en) Immunotherapy with b*07 restricted peptides and combination of peptides against cancers and related methods
IL300841A (en) Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
MX2021010281A (en) Antigen binding proteins that bind bcma.
WO2021173896A8 (en) Materials and methods for modulating an immune response
SG126893A1 (en) Method for the identification of epitopes related to immunogenicity in biopharmaceuticals
WO2024026029A3 (en) Lipid nanoparticles for immunotherapy
WO2021163562A3 (en) Compositions and methods comprising splicing-derived antigens for treating cancer
WO2020185796A9 (en) High avidity wt1 t cell receptors and uses thereof
BR112012014345A2 (en) tmem22 peptides and vaccines including the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23847354

Country of ref document: EP

Kind code of ref document: A2